Outstanding Item
Rituximab for connective tissue disease associated lung disease clinical
commissioning policy
Rituximab for the treatment of primary Sjögren's syndrome (PSS) in adults
clinical commissioning policy
Revision morbid obesity surgery clinical commissioning policy
Rituximab for haemophilia clinical commissioning policy
Treatment as prevention (HIV) clinical commissioning policy
Expected
Number of
Patients to
be Treated
Each Year
120
120
Bedaquiline for TB clinical commissioning policy
378
15
778
additional
over 6 years
25 maximum
Robotic assisted surgery - prostate clinical commissioning policy
5271
Gender identity services clinical commissioning policy
Duopoda for Parkinson's disease clinical commissioning policy
Microprocessor controlled prosthetic knees clinical commissioning policy
3000
75-100 new
patients per
year
500-600
High definition silicone clinical commissioning policy
600-700
Provision of multi grip upper limb prosthesis clinical commissioning policy
115
Hand transplantation clinical commissioning policy
Deep brain stimulation for refractory epilepsy clinical commissioning policy
Uveitis (adults) clinical commissioning policy
2
20
220
Uveitis (children) clinical commissioning policy
110
Intrathecal pumps / drug delivery for cancer pain clinical commissioning
policy
60
Intrathecal pumps / drug delivery for non-malignant pain clinical
commissioning policy
50
Occipital nerve stimulator for cluster headaches and chronic migraine
clinical commissioning policy
80-100
Deep brain stimulation for chronic pain clinical commissioning policy
80 - 100
BRCA (breast cancer) clinical commissioning policy
Sapropterin for children clinical commissioning policy
3500
approximately
to be tested
130
Elosulfase - vimizim for mucopolysaccharidosis IVA clinical commissioning
policy
35 min, 77
max
Viz ataluren for duchenne muscular dystrophy clinical commissioning policy
80
SNS for urinary incontinence and retention clinical commissioning policy
minimum of
25
The number
of index
cases per
annum are
estimated to
be 15869 and
number of
family
member
testing
estimated per
annum to be
8506'
30 - 60
New genetic test recommendations
Rituximab for standard treatment resistant idiopathic membranous
nephropathy Commissioning through Evidence
SABR Commissioning through Evaluation
Sickle cell Commissioning through Evaulation
300
Argus II prosthesis Commissioning through Evaluation
10 per annum
for 3 years
10
Ziconotide for chronic pain Commissioning through Evaluation
20
Rituximab for the treatment of SSNS in paediatrics clinical commissioning
policy is to be discussed at CPAG on Tuesday – 3 March 2015
40-60
patients per
year